BridgeBio Pharma, Inc. announced the FDA approval of Attruby™ (acoramidis), an oral stabilizer of transthyretin (TTR), for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This treatment aims to reduce cardiovascular death…
Versant Ventures has announced the launch of Pep2Tango Therapeutics Inc., a new startup focused on next-generation weight loss treatments. The company will use funds from a significant, undisclosed investment round…
Population Health Research Institute (PHRI), a joint initiative of McMaster University and Hamilton Health Sciences, is celebrating its 25th anniversary as a global leader in health research. Over the past…
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, has announced the appointment of…
Altasciences is pleased to have supported Metsera, Inc., a clinical-stage biopharmaceutical company focused on advancing next-generation treatments for obesity and metabolic diseases, in its nonclinical and early-stage clinical trials. This…
NorthStar Medical Radioisotopes, LLC, a leader in radiopharmaceutical innovation, has entered into a strategic Master Supply Agreement with Cellectar Biosciences, Inc. (NASDAQ: CLRB). Under the agreement, Cellectar will integrate NorthStar’s…
Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, has announced the integration of its advanced AI solutions into routine clinical practice at Institut Curie, one of the world’s…
Trinity Life Sciences, a leader in strategy, insights, and analytics for the life sciences industry, has introduced a groundbreaking approach to evaluating the impact of Field Medical Affairs in its…
Omeros Corporation (Nasdaq: OMER) has shared an update on its ongoing efforts to resubmit the biologics license application (BLA) for narsoplimab, its first-in-class antibody targeting MASP-2, a key enzyme in…
Pfizer Inc. (NYSE: PFE) has announced the appointment of Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development, effective January 1, 2025. Dr.…
Pfizer Inc. (NYSE: PFE) has received marketing authorization from the European Commission (EC) for HYMPAVZI™ (marstacimab) for the routine prevention of bleeding episodes in patients aged 12 years and older,…
Eisai Co., Ltd. has announced the launch of TASFYGO® Tablets 35mg (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer harboring FGFR2 gene…